An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Investigational Vaccine GSK2838504A When Administered to COPD Patients

Trial Profile

An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Investigational Vaccine GSK2838504A When Administered to COPD Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 10 May 2017

At a glance

  • Drugs GSK 2838497A (Primary)
  • Indications Haemophilus infections; Pneumococcal infections; Respiratory tract infections
  • Focus Adverse reactions
  • Acronyms NTHI 004
  • Sponsors GlaxoSmithKline Biologicals
  • Most Recent Events

    • 05 May 2017 Status changed from active, no longer recruiting to completed.
    • 19 Jan 2016 Planned End Date changed from 1 Feb 2017 to 1 Apr 2017 as per ClinicalTrials.gov record.
    • 19 Jan 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Apr 2017 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top